Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 166Polycystic Ovary Syndrome 23Neoplasm Metastasis 10Osteoporosis 7Neoplasms 6Infertility 6Endometrial Neoplasms 5Carcinoma, Intraductal, Noninfiltrating 5Ovarian Neoplasms 4Breast Carcinoma In Situ 4Arthralgia 4Recurrence 3Hereditary Sensory and Autonomic Neuropathies 3Carcinoma, Ductal, Breast 3Breast Neoplasms, Male 3Breast Cancer Metastatic 3Advanced Breast Cancer 3Triple Negative Breast Neoplasms 2Pain 2Leiomyoma 2Fallopian Tube Neoplasms 2Estrogen Receptor-positive Breast Cancer 2Carcinoma, Lobular 2Bone Diseases, Metabolic 2Uterine Neoplasms 1Patient Acceptance of Health Care 1Ovarian Cysts 1Osteitis Deformans 1Obesity 1Neoplastic Cells, Circulating 1

Interventions

seribantumab 2zenocutuzumab 1patritumab 1exemestane 1Vinorelbine 1Trastuzumab 1Letrozole 1In Situ Hybridization, Fluorescence 1Fulvestrant 1Erlotinib Hydrochloride 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Lethal Congenital Contracture Syndrome 2 × Letrozole × Clear all
NCT03321981 2024-03-07

MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.

Merus B.V.

Phase 2 Completed
105 enrolled 23 charts

Lethal Congenital Contracture Syndrome 2

Data powered by HemOnc (CC BY 4.0) Colophon âš¡